CytRx (QB) Stock Price

0.0073 (1.49%)
Volume 57,095
Bid Price 0.4903
Ask Price 0.593
News -
Day High 0.52


52 Week Range


Day Low 0.49
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CytRx Corp (QB) CYTR OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0073 1.49% 0.4975 16:05:56
Open Price Low Price High Price Close Price Prev Close
0.49 0.49 0.52 0.4975 0.4902
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
36 57,095 $ 0.499395 $ 28,513 - 0.467 - 5.00
Last Trade Time Type Quantity Stock Price Currency
15:58:03 100 $ 0.4975 USD


Draw Mode:

CytRx Corp (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 18.30M 36.78M 30.93M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
51.99k $ - - - -

more financials information »

CytRx (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CYTR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.56970.590.4850.520812686,469-0.0722-12.67%
1 Month0.750.850.4850.620041668,685-0.2525-33.67%
3 Months0.60520.860.4670.592053773,802-0.1077-17.8%
6 Months1.584.700.4671.69206,810-1.08-68.51%
1 Year0.755.000.4671.87190,541-0.2525-33.67%
3 Years0.2555.000.211.26139,1580.242595.1%
5 Years0.2555.000.211.26139,1580.242595.1%

CytRx (QB) Description

CytRx Corporation is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been outlicensed to NantCell, Inc (now called ImmunityBio, Inc.). In addition, CytRx's other drug candidate, arimoclomol, has been sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA), which sale included conditional future milestone and royalty payments. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). Orphazyme has announced they will be submitting a NDA with the U.S. FDA and a MAA with the EMA in the first half and second half of 2020, respectively, for NPC. CytRx Corporation's website is CytRx's wholly owned subsidiary, Centurion BioPharma Corporation, is focused on the development of personalized medicine that is designed to transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADR(TM) (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADR(TM)-derived therapies. A critical element of the LADR(TM) platform is its ability to bind anti-cancer molecules to circulating albumin, the most ubiquitous protein in human blood plasma, and then to release the highly potent cytotoxic payload at the tumor site. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules. Centurion BioPharma Corporation's website is
Your Recent History
CytRx (QB)
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211209 10:54:59